A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma

Cancer Research

Volumn 63, Issue 2, 2003, Pages 484-490

  Adam, Rosalyn M ^a   Danciu, Theodora ^a   McLellan, Dawn L ^a   Borer, Joseph G ^a   Lin, Jianqing ^a   Zurakowski, David ^a   Weinstein, Michael H ^b   Rajjayabun, Paul H ^c   Mellon, J Kilian ^d   Freeman, Michael R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGENIC AGENT; PROTEIN PRECURSOR;

ADULT; AGED; ANIMAL CELL; ANTIBODY LABELING; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0037439921     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Das, S. K., Wang, X. N., Paria, B. C., Damm, D., Abraham, J. A., Klagsbrun, M., Andrews, G. K., and Dey, S. K. Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation. Development (Camb.), 120: 1071-1083, 1994.
2. Raab, G., Kover, K., Paria, B. C., Dey, S. K., Ezzell, R. M., and Klagsbrun, M. Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor. Development (Camb.), 122: 637-645, 1996.
3. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., and Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem., 272: 31730-31737, 1997.
4. Dethlefsen, S. M., Raab, G., Moses, M. A., Adam, R. M., Klagsbrun, M., and Freeman, M. R. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J. Cell. Biochem., 69: 143-153, 1998.
5. Takemura, T., Kondo, S., Homma, T., Sakai, M., and Harris, R. C. The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J. Biol. Chem., 272: 31036-31042, 1997.
6. Miyoshi, E., Higashiyama, S., Nakagawa, T., Hayashi, N., and Taniguchi, N. Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J. Biol. Chem., 272: 14349-14355, 1997.
7. Lin, J., Hutchinson, L., Gaston, S. M., Raab, G., and Freeman, M. R. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor. A unique role for proHB-EGF in cell survival regulation. J. Biol. Chem., 276: 30127-30132, 2001.
8. Naglich, J. G., Metherall, J. E., Russell, D. W., and Eidels, L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell, 69: 1051-1061, 1992.
9. Freeman, M. R., Yoo, J. J., Raab, G., Soker, S., Adam, R. M., Schneck, F. X., Renshaw, A. A., Klagsbrun, M., and Atala, A. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J. Clin. Investig., 99: 1028-1036, 1997.
10. Park, J. M., Borer, J. G., Freeman, M. R., and Peters, C. A. Stretch activates heparin-binding EGF-like growth factor expression in bladder smooth muscle cells. Am. J. Physiol., 275: C1247-C1254, 1998.
11. Borer, J. G., Park, J. M., Atala, A., Nguyen, H. T., Adam, R. M., Retik, A. B., and Freeman, M. R. Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. Lab. Investig., 79: 1335-1345, 1999.
12. Keay, S., Zhang, C. O., Kagen, D. I., Hise, M. K., Jacobs, S. C., Hebel, J. R., Gordon, D., Whitmore, K., Bodison, S., and Warren, J. W. Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. J. Urol., 158: 1983-1988, 1997.
13. Keay, S., Kleinberg, M., Zhang, C. O., Hise, M. K., and Warren, J. W. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production. J. Urol., 164: 2112-2118, 2000.
14. Keay, S. K., Zhang, C., Shoenfelt, J., Erickson, D. R., Whitmore, K., Warren, J. W., Marvel, R., and Chai, T. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology, 57: 9-14, 2001.
15. Chai, T. C., Zhang, C. O., Shoenfelt, J. L., Johnson, H. W., Jr., Warren, J. W., and Keay, S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J. Urol., 163: 1440-1444, 2000.
16. Ruck, A., and Paulie, S. EGF, TGF α, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res., 18: 1447-1452, 1998.
17. Thogersen, V. B., Sorensen, B. S., Poulsen, S. S., Omtoft, T. F., Wolf, H., and Nexo, E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res., 61: 6227-6233. 2001.
18. Nguyen, H. T., Adam, R. M., Bride, S. H., Park, J. M., Peters, C. A., and Freeman, M. R. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells. Am. J. Physiol. Cell Physiol., 279: C1155-C1167, 2000.
19. Armitage, P. and Berry, G. Statistical Methods in Medical Research, 3rd ed., pp. 453-464, Cambridge, MA: Blackwell Science, 1994.
20. Lang, T. A., and Secic, M. Testing for relationships. In: How to Report Statistics in Medicine, pp. 93-104. Philadelphia, PA: American College of Physicians, 1997.
21. Grunkemeier, G. L., and Jin, R. Receiver operating characteristic curve analysis of clinical risk models. Ann. Thoracic Surg., 72: 323-326, 2001.
22. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
23. Hosmer, D. W., and Lemeshow, S. Applied Survival Analysis. Regression Modeling of Time to Event Data, pp. 28-47. New York, NY, Wiley-Interscience, 1999.
24. Cox, D. R., and Oakes, D. Analysis of Survival Data. London, UK, CRC Press, 1984.
25. Raab, G., and Klagsbrun, M. Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta, 1333: F179-F199, 1997.
26. Johnson, G. R., Saeki, T., Auersperg, N., Gordon, A. W., Shoyab, M., Salomon, D. S., and Stromberg, K. Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithelial cells: nuclear localization of endogenous amphiregulin. Biochem. Biophys. Res. Commun., 180: 481-488, 1991.
27. Modrell, B., McDonald, V. L., and Shoyab, M. The interaction of amphiregulin with nuclei and putative nuclear localization sequence binding proteins. Growth Factors, 7: 305-314, 1992.
28. Nylander, N., Smith, L. T., Underwood, R. A., and Piepkom, M. Topography of amphiregulin expression in cultured human keratinocytes: colocalization with the epidermal growth factor receptor and CD44. In Vitro Cell Dev. Biol. Anim., 34: 182-188, 1998.
29. Goishi, K., Higashiyama, S., Klagsbrun, M., Nakano, N., Umata, T., Ishikawa, M., Mekada, E., and Taniguchi, N. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol. Biol. Cell, 6: 967-980, 1995.
30. Iwamoto, R., Handa, K., and Mekada, E. Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J. Biol. Chem., 274: 25906-25912, 1999.
31. Higashiyama, S., Lau, K., Besner, G. E., Abraham, J. A., and Klagsbrun, M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J. Biol. Chem., 267: 6205-6212. 1992.
32. Ito, Y., Takeda, T., Higashiyama, S., Sakon, M., Wakasa, K. I., Tsujimoto, M., Monden, M., and Matsuura, N. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol. Rep., 8: 903-907, 2001.
33. Ito, Y., Takeda, T., Higashiyama, S., Noguchi, S., and Matsuura, N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res. Treat., 67: 81-85, 2001.
34. Ito, Y., Higashiyama, S., Takeda, T., Yamamoto, Y., Wakasa, K. I., and Matsuura, N. Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int. J. Pancreatol., 29: 47-52, 2001.
35. Grasl-Kraupp, B., Schausberger, E., Hufnagl, K., Gerner, C., Low-Baselli, A., Rossmanith, W., Parzefall, W., and Schulte-Hermann, R. A novel mechanism for mitogenic signaling via pro-transforming growth factor α within hepatocyte nuclei. Hepatology, 35: 1372-1380, 2002.
36. Kitadai, Y., Yasui, W., Yokozaki, H., Kuniyasu, H., Ayhan, A., Haruma, K., Kajiyama, G., Johnson, G. R., and Tahara, E. Expression of amphiregulin, a novel gene of the epidermal growth factor family, in human gastric carcinomas. Jpn. J. Cancer Res., 84: 879-884, 1993.
37. Mellon, K., Wright, C., Kelly, P., Home, C. H., and Neal, D. E. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J. Urol., 153: 919-925, 1995.
38. Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R., and Harris, A. L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (Phila.), 65: 1619-1625, 1990.
39. Messing, E. M. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res., 50: 2530-2537, 1990.
40. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell. Biol., 3: 802-808, 2001.
41. Marti, U., Ruchti, C., Kampf, J., Thomas, G. A., Williams, E. D., Peter, H. J., Gerber, H., and Burgi, U. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid, 11: 137-145, 2001.
42. Okamura, K., Kobayashi, I., Matsuo, K., Kiyoshima, T., Yamamoto, K., Miyoshi, A., and Sakai, H. Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analysed by computer image analyser: correlation with histological grade and metastatic behaviour. Histopathology, 31: 540-548, 1997.
43. Lipponen, P., and Eskelinen, M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer, 69: 1120-1125, 1994.
44. Lee, C. C., Yamamoto, S., Morimura, K., Wanibuchi, H., Nishisaka, N., Ikemoto, S., Nakatani, T., Wada, S., Kishimoto, T., and Fukushima, S. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer (Phila.), 79: 780-789, 1997.
45. Shin, K. Y., Kong, G., Kim, W. S., Lee, T. Y., Woo, Y. N., and Lee, J. D. Overexpression of cyclin DI correlates with early recurrence in superficial bladder cancers. Br. J. Cancer, 75: 1788-1792, 1997.
46. Tut, V. M., Braithwaite, K. L., Angus, B., Neal, D. E., Lunec, J., and Mellon, J. K. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br. J. Cancer, 84: 270-275, 2001.
47. Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am. J. Pathol., 155: 1129-1136, 1999.
48. Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin. Cancer Res., 6: 3131-3138, 2000.
49. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., and Cote, R. J. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst. (Bethesda), 90: 1072-1079, 1998.
50. Qureshi, K. N., Griffiths, T. R., Robinson, M. C., Marsh, C., Roberts, J. T., Lunec, J., Neal, D. E., and Mellon, J. K. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 51: 1234-1240, 2001.
51. Yamazaki, F., Aragane, Y., Kawada, A., and Tezuka, T. Immunohistochemical detection for nuclear β-catenin in sporadic basal cell carcinoma. Br. J. Dermatol., 145: 771-777, 2001.
52. Park, W. S., Oh, R. R., Park, J. Y., Kim, P. J., Shin, M. S., Lee, J. H., Kim, H. S., Lee, S. H., Kim, S. Y., Park, Y. G., An, W. G., Jang, J. J., Yoo, N. J., and Lee, J. Y. Nuclear localization of β-catenin is an important prognostic factor in hepatoblastoma. J. Pathol., 193: 483-490, 2001.
53. Nhieu, J. T., Renard, C. A., Wei, Y., Cherqui, D., Zafrani, E. S., and Buendia, M. A. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol., 155: 703-710, 1999.
54. Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T. G., Carcangiu, M. L., and Rimm, D. L. Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res., 59: 1811-1815, 1999.
55. Delrieu, I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett., 468: 6-10, 2000.
56. Iberg, N., Rogelj, S., Fanning, P., and Klagsbrun, M. Purification of 18- and 22-kDa forms of basic fibroblast growth factor from rat cells transformed by the ras oncogene. J. Biol. Chem., 264: 19951-19955, 1989.
57. Vagner, S., Touriol, C., Galy, B., Audigier, S., Gensac, M. C., Amalric, F., Bayard, F., Prats, H., and Prats, A. C. Translation of CUG- but not AUG-initiated forms of human fibroblast growth factor 2 is activated in transformed and stressed cells. J. Cell Biol., 135: 1391-1402, 1996.
58. 2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res. 57: 1364-1370, 1997.
59. Joy, A., Moffett, J., Neary, K., Mordechai, E., Stachowiak, E. K., Coons, S., Rankin-Shapiro, J, Florkiewicz, R. Z., and Stachowiak, M. K. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene, 14: 171-183, 1997.
60. Okada-Ban, M., Moens, G., Thiery, J. P., and Jouanneau, J. Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene, 18: 6719-6724, 1999.
61. Massfelder, T., Dann, P., Wu, T. L., Vasavada, R., Helwig, J. J., and Stewart, A. F. Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting. Proc. Natl. Acad. Sci. USA, 94: 13630-13635, 1997.
62. Henderson, J. E., Amizuka, N., Warshawsky, H., Biasotto, D., Lanske, B. M., Goltzman, D., and Karaplis, A. C. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol. Cell. Biol., 15: 4064-4075, 1995.
63. Henderson, J. E., He, B., Goltzman, D., and Karaplis, A. C. Constitutive expression of parathyroid hormone-related peptide (PTHrP) stimulates growth and inhibits differentiation of CFK2 chondrocytes. J. Cell. Physiol., 169: 33-41, 1996.
64. 1 phase growth arrest of vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab., 279: E60-E67, 2000.
65. Jiang, B., Morimoto, S., Fukuo, K., Yasuda, O., Chen, S., and Ogihara, T. Role of parathyroid hormone-related protein in the proliferation of vascular smooth muscle cells. Miner. Electrolyte Metab., 21: 157-160, 1995.